Intravesical Chemotherapy for Bladder Cancer
Intravesical chemotherapy means anti-cancer medicine is placed directly into the bladder through a small catheter and held there for a prescribed period. It is used mainly for non-muscle-invasive bladder cancer (NMIBC), where the tumour is confined to the bladder lining or lamina propria. A single immediate instillation after TURBT can reduce recurrence in selected low- and intermediate-risk tumours, while repeated courses of intravesical chemotherapy are options for some intermediate-risk disease and for selected recurrences. Common agents include mitomycin and gemcitabine; combination regimens such as gemcitabine plus docetaxel are also used in certain higher-risk or BCG-failure settings. The exact regimen depends on tumour risk, previous treatment, drug availability and local protocol.
How does intravesical chemotherapy work?
The drug contacts the bladder lining directly, exposing residual microscopic tumour cells to a high local concentration while limiting systemic exposure. The medicine is then passed out in the urine. Because treatment stays mainly within the bladder, side effects are usually urinary rather than the hair loss, severe nausea or bone-marrow suppression associated with intravenous chemotherapy.
When is a single immediate dose used?
After complete TURBT of a tumour that appears low or intermediate risk, a single intravesical chemotherapy instillation may be given soon after surgery to reduce implantation and early recurrence. It is not given when bladder perforation is suspected, resection is very extensive, or significant postoperative bleeding makes instillation unsafe.
When are repeated courses used?
- Intermediate-risk NMIBC where a course of intravesical chemotherapy is preferred to BCG.
- Recurrent low-grade disease where repeated TURBT alone would create excessive treatment burden.
- Selected patients with high-grade recurrence after BCG who are unfit for or decline cystectomy, using specialist salvage regimens.
- Clinical-trial or guideline-supported bladder-preservation pathways depending on tumour biology and previous treatment.
Intravesical chemotherapy vs BCG
| Issue | Intravesical chemotherapy | BCG |
|---|---|---|
| Type of treatment | Anti-cancer drug placed in bladder | Local immunotherapy with attenuated BCG organism |
| Typical role | Low/intermediate-risk recurrence reduction; selected salvage use | High-risk NMIBC and CIS; some intermediate-risk disease |
| Systemic infection risk | Very low when bladder is intact | Rare systemic BCG infection is a recognized serious complication |
| Typical side effects | Burning, frequency, chemical cystitis, rash depending on drug | Burning, frequency, haematuria, fever/flu-like symptoms |
| Choice | Based on recurrence/progression risk and prior therapy | Based on risk, BCG availability, tolerability and oncological need |
What happens during an instillation?
- The bladder is usually emptied through a small catheter.
- The chemotherapy solution is placed into the bladder.
- The catheter is removed or temporarily clamped depending on protocol.
- You hold the medicine for the prescribed time if comfortable.
- You void according to the centre’s safety instructions and follow any toilet-hygiene precautions provided.
Common side effects
- Urinary burning and frequency.
- Urgency or bladder discomfort.
- Small amount of blood in urine.
- Chemical cystitis after repeated treatment.
- Skin irritation if the drug contacts the external genital skin; careful hygiene reduces this.
Severe whole-body chemotherapy side effects are uncommon because absorption is limited, but systemic exposure can increase if the bladder wall is injured or perforated.
When to contact your team urgently
- Fever or systemic illness.
- Inability to pass urine.
- Heavy bleeding or clots.
- Severe escalating pelvic pain.
- New rash, swelling or breathing difficulty suggesting an allergic reaction.
Follow-up after intravesical chemotherapy
Cystoscopy remains essential because intravesical treatment reduces recurrence risk but does not eliminate it. The follow-up schedule depends on whether the original tumour was low, intermediate or high risk and on the response to treatment.
Intravesical chemotherapy is not the same as intravenous chemotherapy
Intravesical drugs are placed directly inside the bladder and are intended to act mainly on the bladder lining. Systemic absorption is limited compared with intravenous chemotherapy, so hair loss, severe nausea and bone-marrow suppression are not expected in the same way. The main problems are usually bladder irritation, chemical cystitis and urinary symptoms.
Common intravesical agents include mitomycin C and gemcitabine, but the choice and schedule depend on tumour risk, previous treatment, local availability and whether the aim is a single immediate postoperative instillation or a course of adjuvant therapy. The drug should not be instilled when bladder perforation is suspected or when other safety concerns make intravesical treatment inappropriate.
Why the immediate postoperative instillation is time-sensitive
For appropriate low-risk and selected intermediate-risk tumours, a single dose of intravesical chemotherapy soon after TURBT can destroy free-floating tumour cells and reduce implantation on the raw resection surface. The benefit is greatest when given promptly, typically within the first postoperative day.
It is omitted when bladder perforation is suspected, bleeding is significant, resection is very extensive or another safety concern exists. Missing the dose for a valid safety reason is not a treatment error; patient safety takes priority over the theoretical recurrence benefit.
Consultation checklist
- TURBT pathology and risk category.
- Previous intravesical drugs and number of instillations.
- History of BCG and any BCG failure.
- Recent urine culture if symptomatic.
- Kidney function and major allergies.
- Cystoscopy timeline and recurrence history.
FAQs
Is intravesical chemotherapy the same as IV chemotherapy?
No. Intravesical treatment is placed directly inside the bladder and usually causes much less systemic exposure.
Will I lose my hair?
Hair loss is not expected from standard intravesical chemotherapy because systemic absorption is low.
Why can’t chemotherapy be put in the bladder after every TURBT?
It is unsafe if there may be bladder perforation, extensive deep resection or significant bleeding, and not every tumour gains the same benefit.
Is gemcitabine better than mitomycin?
Both are established intravesical drugs. Choice depends on the clinical setting, previous treatment, tolerability, evidence for the specific risk group and availability.
Can intravesical chemotherapy replace cystectomy for BCG-unresponsive high-grade disease?
For fit patients, radical cystectomy remains the oncologically preferred treatment in many BCG-unresponsive situations. Intravesical salvage regimens are alternatives when cystectomy is declined or unsuitable and require close surveillance.
Related reading
- Non-Muscle Invasive Bladder Cancer
- BCG Therapy for Bladder Cancer
- TURBT Surgery Explained
- Bladder Cancer Recurrence
- Follow-Up Cystoscopy After Bladder Cancer
- Chemotherapy for Advanced Prostate Cancer
- Chemotherapy and Immunotherapy for Advanced Bladder Cancer
- Urologist in Latur
References
- European Association of Urology (EAU). EAU Guidelines on Non-Muscle-Invasive Bladder Cancer. 2026 edition https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer
- National Cancer Institute. Bladder Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
- American Urological Association/SUO. Non-Muscle Invasive Bladder Cancer Guideline (2016; amended 2024) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline
- European Association of Urology Nurses. Intravesical instillation with mitomycin C and bacillus Calmette-Guérin in non-muscle-invasive bladder cancer. 2026 https://nurses.uroweb.org/guidelines/intravesical-instillation